

## Transparency notification BlackRock, Inc.

Brussels (Belgium), 23 August 2024 – 20:00 (CEST) – Regulated information

### 1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from BlackRock, Inc. (having its registered office at 50 Hudson Yards, New York, NY, 10001, U.S.A.), dated 20 August 2024.

BlackRock, Inc. notified that, following a disposal of UCB shares with voting rights by its affiliates, its shareholding in UCB SA decreased and crossed downwards the 5% threshold on 19 August 2024.

On 19 August 2024, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 695 621 UCB shares with voting rights or assimilated financial instruments, representing 4,98% of the total number of shares issued by the company (194 505 658), versus 5,01% (9 745 869 UCB shares or assimilated financial instruments) in the previous notification dated 16 August 2024.

### 2. Content of the notification

- **Reason for the notification:** Acquisition or disposal of voting securities or voting rights.
- **Notification by:** A parent undertaking or a controlling person.
- **Persons subject to the notification requirement:**

# UCB News

Name	Address (for legal entities)
BlackRock, Inc.	50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock (Netherlands) B.V.	Rembrandt Tower, 17th floor, Amstelplein, Amsterdam, Netherlands
BlackRock (Singapore) Limited	20 Anson Road #18-01, Singapore, 79912, Singapore
BlackRock Advisors (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Advisors, LLC	50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock Asset Management Canada Limited	161 Bay Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada
BlackRock Asset Management Deutschland AG	Lenbachplatz 1 1st Floor, Munich, 80333-MN3, Germany
BlackRock Asset Management North Asia Limited	15/F, 16/F, 17/F Citibank Tower & 17/F ICBC Tower, 3 Garden Road, Central, Hong Kong
BlackRock Financial Management, Inc.	50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock Fund Advisors	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Institutional Trust Company, National Association	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Investment Management (Australia) Limited	Level 37 Chifley Tower, 2 Chifley Square, Sydney NSW 2000, Australia
BlackRock Investment Management (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Investment Management, LLC	1 University Square Drive, Princeton, NJ, 8540, U.S.A.
BlackRock Japan Co., Ltd.	1-8-3 Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217, Japan
Aperio Group, LLC	3 Harbor Dr Suite 204, Sausalito, CA 94965, United States

- **Date on which the threshold is crossed:** 19 August 2024.
- **Threshold crossed (in %):** 5%.
- **Denominator:** 194 505 658.
- **Notified details:**

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
BlackRock, Inc.	0	0		0,00%	
BlackRock (Netherlands) B.V.	3.219	3.219		0,00%	
BlackRock (Singapore) Limited	32.954	5.770		0,00%	
BlackRock Advisors (UK) Limited	1.448.868	1.636.170		0,84%	
BlackRock Advisors, LLC	87.107	87.011		0,04%	
BlackRock Asset Management Canada Limited	134.457	134.108		0,07%	
BlackRock Asset Management Deutschland AG	179.037	179.037		0,09%	
BlackRock Asset Management North Asia Limited	3.524	3.524		0,00%	
BlackRock Financial Management, Inc.	188.485	71.001		0,04%	
BlackRock Fund Advisors	2.510.916	2.511.531		1,29%	
BlackRock Institutional Trust Company, National Association	1.619.238	1.616.594		0,83%	
BlackRock Investment Management (Australia) Limited	51.010	51.010		0,03%	
BlackRock Investment Management (UK) Limited	2.639.044	2.539.754		1,31%	
BlackRock Investment Management, LLC	519.533	516.608		0,27%	
BlackRock Japan Co., Ltd.	230.038	231.530		0,12%	
Aperio Group, LLC	39.982	39.982		0,02%	
Subtotal	9.687.413	9.626.848		4,95%	
<b>TOTAL</b>		<b>9.626.848</b>	<b>0</b>	<b>4,95%</b>	<b>0,00%</b>

B) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
BlackRock Advisors (UK) Limited	Securities Lent			7.476	0,00%	physical
BlackRock Fund Advisors	Securities Lent			31.850	0,02%	physical
BlackRock Institutional Trust Company, National Association	Securities Lent			15.744	0,01%	physical
BlackRock Investment Management (UK) Limited	Securities Lent			6.409	0,00%	physical
BlackRock Financial Management, Inc.	Contract for Difference			1.148	0,00%	cash
BlackRock Institutional Trust Company, National Association	Contract for Difference			1.536	0,00%	cash
Aperio Group, LLC	Depository Receipt			4.610	0,00%	
<b>TOTAL</b>				<b>68.773</b>	<b>0,04%</b>	

TOTAL (A & B)	# of voting rights	% of voting rights
<b>CALCULATE</b>	9.695.621	4,98%

- **Chain of controlled undertakings through which the holding is effectively held:**

Please see the full chain of control in the 'Chain of Control' tab.

- **Additional information:** The disclosure obligation arose due to total holdings in voting rights for BlackRock, Inc. going below 5%.

### 3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following [link](#).

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following [link](#).

---

**For further information, contact UCB:**

**Investor Relations**

Antje Witte  
T +32 2 559 94 14  
[antje.witte@ucb.com](mailto:antje.witte@ucb.com)

**Corporate Communications**

Laurent Schots  
T+32 2 559 92 64  
[laurent.schots@ucb.com](mailto:laurent.schots@ucb.com)

**About UCB**

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB\_news